<qa>  What is the benefit-risk balance of Cimicifuga racemosa extract?The benefit-risk-balance of the isopropanolic Cimicifuga racemosa extract iCR is compared with tibolone in menopausal symptoms treatment. Menopausal patients aged 40 - 60 years and with a Kupperman Menopause Index KMI equal or more than 15 participate and were assigned to either iCR corresponding to 40 mg crude drugday n122 or tibolone 2,5 mgday n122 orally. The primary endpoint is the benefit-risk balance at end of treatment. 